Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis.

Next Previous
Search
Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jan 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Briakinumab (Primary) ; Etanercept
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Abbott Laboratories

    • Most Recent Events

    • 01 Jan 2018 Results comparing Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis in patients data from M10-114, M10-315, REVEAL and CHAMPION trials (n=1692), published in the Value in Health
    • 08 Mar 2016 Pooled analysis (n=1692) of 4 trials (NCT00237887, NCT00235820, NCT00691964, NCT00710580) were presented at the 74th Annual Meeting of the American Academy of Dermatology.
    • 08 Feb 2011 Results presented at the 69th Annual Meeting of the American Academy of Dermatology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top